First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Short Interest Update

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) was the target of a large decline in short interest during the month of September. As of September 15th, there was short interest totaling 19,031 shares, a decline of 85.8% from the August 31st total of 134,463 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 35,950 shares, the short-interest ratio is presently 0.5 days.

First Trust Nasdaq Pharmaceuticals ETF Stock Performance

Shares of NASDAQ FTXH traded down $0.24 during midday trading on Friday, hitting $41.33. 5,867 shares of the stock traded hands, compared to its average volume of 214,261. The firm has a market capitalization of $1.19 billion, a P/E ratio of 14.51 and a beta of 0.46. First Trust Nasdaq Pharmaceuticals ETF has a one year low of $27.40 and a one year high of $42.87. The firm has a 50-day moving average of $40.51 and a two-hundred day moving average of $37.03.

First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Thursday, September 24th will be given a dividend of $0.0113 per share. This represents a $0.05 dividend on an annualized basis and a yield of 0.1%. This is a drop from First Trust Nasdaq Pharmaceuticals ETF’s previous quarterly dividend of $0.0920. The ex-dividend date is Thursday, September 24th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of FTXH. Compass Financial Management LLC purchased a new position in First Trust Nasdaq Pharmaceuticals ETF in the second quarter worth about $29,000. Flputnam Investment Management Co. purchased a new stake in shares of First Trust Nasdaq Pharmaceuticals ETF during the 4th quarter valued at about $230,000. Vivaldi Capital Management LP increased its position in shares of First Trust Nasdaq Pharmaceuticals ETF by 16.0% during the 1st quarter. Vivaldi Capital Management LP now owns 12,590 shares of the company’s stock valued at $433,000 after purchasing an additional 1,741 shares during the last quarter. Finally, Nilsine Partners LLC lifted its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 3.5% in the 2nd quarter. Nilsine Partners LLC now owns 28,057 shares of the company’s stock worth $1,071,000 after purchasing an additional 937 shares during the period.

About First Trust Nasdaq Pharmaceuticals ETF

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.